Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2025-08-14 6:13 pm Sale | 2025-06-30 | 13G | UroGen Pharma Ltd. URGN | RA Capital Management, L.P. | 0 0.000% | -3,206,271 (Position Closed) | Filing History |
| 2025-08-12 4:30 pm Purchase | 2025-08-05 | 13G | UroGen Pharma Ltd. URGN | Paradigm BioCapital Advisors LP | 2,332,066 5.000% | 2,332,066 (New Position) | Filing History |
| 2025-08-06 3:56 pm Purchase | 2025-06-30 | 13G | UroGen Pharma Ltd. URGN | MORGAN STANLEY MS | 2,488,299 5.400% | 1,735,438 (+230.51%) | Filing History |
| 2025-08-05 5:00 pm Sale | 2025-06-30 | 13G | UroGen Pharma Ltd. URGN | Soleus Capital Master Fund, L.P. | 2,185,000 4.700% | -140,000 (-6.02%) | Filing History |
| 2025-07-29 4:56 pm Purchase | 2025-06-30 | 13G | UroGen Pharma Ltd. URGN | Cowen Financial Products LLC | 3,190,510 6.900% | 538,010 (+20.28%) | Filing History |
| 2025-07-16 7:02 pm Purchase | 2025-06-30 | 13G | UroGen Pharma Ltd. URGN | BlackRock Inc. BLK | 2,284,206 5.000% | 2,284,206 (New Position) | Filing History |
| 2025-06-16 5:00 pm Purchase | 2025-06-13 | 13G | UroGen Pharma Ltd. URGN | Soleus Capital Master Fund, L.P. | 2,325,000 5.000% | 2,325,000 (New Position) | Filing History |
| 2025-06-13 11:38 am Purchase | 2025-06-09 | 13G | UroGen Pharma Ltd. URGN | Cowen Financial Products LLC | 2,652,500 5.800% | 2,652,500 (New Position) | Filing History |
| 2025-06-09 7:19 pm Sale | 2025-06-05 | 13D | UroGen Pharma Ltd. URGN | Monograph Capital Holdings Advisors, LLC | 838,615 1.900% | -823,712 (-49.55%) | Filing History |
| 2025-05-15 4:53 pm Unchanged | 2025-03-31 | 13G | UroGen Pharma Ltd. URGN | RA Capital Management, L.P. | 3,206,271 7.000% | 0 (Unchanged) | Filing History |
| 2025-05-12 09:02 am Sale | 2025-03-31 | 13G | UroGen Pharma Ltd. URGN | Adage Capital Management, L.P. | 1,277,000 2.770% | -1,651,086 (-56.39%) | Filing History |
| 2025-03-17 1:23 pm Unchanged | 2025-03-11 | 13G | UroGen Pharma Ltd. URGN | MENORA MIVTACHIM HOLDINGS LTD. | 2,303,031 4.990% | 0 (Unchanged) | Filing History |
| 2025-02-12 09:34 am Sale | 2024-12-31 | 13G | UroGen Pharma Ltd. URGN | Adage Capital Management, L.P. | 2,928,086 6.940% | -807,655 (-21.62%) | Filing History |
| 2025-02-05 10:09 am Sale | 2024-12-31 | 13G | UroGen Pharma Ltd. URGN | MORGAN STANLEY MS | 752,861 1.800% | -1,419,466 (-65.34%) | Filing History |
| 2024-11-18 06:16 am Purchase | 2024-03-14 | 13D | Eloxx Pharmaceuticals, Inc. ELOX | Pontifax Management III G.P. (2011) Ltd. | 1,485,168 4.400% | 1,448,564 (+3957.37%) | Filing History |
| 2024-11-14 7:46 pm Sale | 2024-09-30 | 13G | UroGen Pharma Ltd. URGN | Point72 Asset Management, L.P. | 1,520,007 3.600% | -1,049,819 (-40.85%) | Filing History |
| 2024-11-14 5:46 pm Purchase | 2024-09-30 | 13G | UroGen Pharma Ltd. URGN | RA Capital Management, L.P. | 3,206,271 7.100% | 122,713 (+3.98%) | Filing History |
| 2024-11-14 4:47 pm Sale | 2024-09-30 | 13G | UroGen Pharma Ltd. URGN | Great Point Partners, LLC | 758,786 1.800% | -1,861,759 (-71.04%) | Filing History |
| 2024-11-14 12:04 pm Unchanged | 2024-09-30 | 13G | UroGen Pharma Ltd. URGN | MENORA MIVTACHIM HOLDINGS LTD. | 2,303,031 5.470% | 0 (Unchanged) | Filing History |
| 2024-11-14 08:37 am Unchanged | 2024-09-30 | 13G | UroGen Pharma Ltd. URGN | COWEN AND COMPANY, LLC | 1,796,589 4.300% | 0 (Unchanged) | Filing History |